News

The University of Oxford has launched the first study of ChAdOx1 nCoV-19 Covid-19 vaccine in children and young adults. The single-blind, randomised phase II trial, launched along with three partner sites in London, Southampton and Bristol, will analyse the vaccine’s...

BioIVT, a leading provider of research models and services for drug and diagnostic development, introduced its COVID-19 Vaccination Panel, composed of pre- and post-vaccination serum or PBMC samples, to enable researchers to study blood donors’ vaccine-generated immune response. BioIVT has...

Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd., is pleased to partner with The International Diabetes Federation (IDF) as the first biosimilar insulins company to promote and support IDF’s Core Mission...

Japan’s Health Ministry has approved Pfizer’s Covid-19 vaccine as the Summer Olympic Games begin in July. The approval marks the first in the country as it steps up efforts to fight the third wave of infections. After a government panel recommended...

Enrollment has begun to test additional investigational drugs in the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) programme. ACTIV is a public-private partnership programme to create a coordinated research strategy that prioritizes and speeds development of promising Covid-19 treatments and...

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, the company’s mRNA-based COVID-19 vaccine candidate,...

The UK government has announced an additional £1.5 million of funding to develop a new treatment for gonorrhoea. This investment, on top of £3.5 million committed in 2019, will support the Global Antibiotic Research and Development Partnership (GARDP) in the...